| 1 |
34739847 | PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs. | 2021 Dec 14 |
1 |
| 2 |
27284008 | Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. | 2016 Aug 5 |
1 |
| 3 |
27758865 | An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells. | 2016 Nov 18 |
1 |
| 4 |
26195630 | Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9. | 2015 Sep 18 |
2 |
| 5 |
24808179 | Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9. | 2014 Jun 20 |
6 |
| 6 |
23105118 | The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. | 2012 Dec 21 |
1 |
| 7 |
21324305 | Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor. | 2011 Mar 11 |
1 |
| 8 |
18799458 | Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. | 2008 Nov 14 |
1 |
| 9 |
17461796 | The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. | 2007 Jun |
2 |